Cure8 research brief
The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial stratification.
Clinicians and researchers studying IBD immunology or biomarker development; patients and advocates interested in advances toward personalized stratification for UC.
The report analysed intestinal tissue and paired blood from patients (54 CD, 74 UC) and controls using a 29-marker spectral cytometry panel with both hierarchical gating and unsupervised clustering.
The team identified numerous mucosal and circulating immune subsets and clusters and found disease-specific patterns: CD showed a mainly T-cell–biased mucosal signature while UC had a mixed infiltrate including higher proportions of NK, NKT and IgG+ B cells.
The key practical point highlighted is that mucosal (tissue) immune profiles varied more across UC subgroups (by sex, age, and endoscopic severity) than across CD subgroups, suggesting tissue sampling could aid patient stratification in UC. The authors also note that blood immune profiles were less reflective of mucosal alterations.
This brief is grounded in the article abstract (structured content depth: abstract). The study reports cohort-based immunophenotyping; it does not report intervention results or clinical recommendations.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests ulcerative colitis shows greater mucosal immune variability across sex, age and severity than Crohn’s disease, which could affect how patients are grouped for research or future personalized...
Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
